ClinicalTrials.gg
RecruitingNCT07097298Updated Dec 1, 2025

Empathy and (Self-)Compassion in Parkinson's Disease Patients and Caregivers

An interventional study of empathy and compassion training in Parkinson Disease(PD), sponsored by Alain Kaelin. Recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Alain Kaelin · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
32nd of 67
30 · median 30
Started
2025
with 7 others
No phase
49 of 85
23 open now
Primary completion
2027-07
later than 18 of 33 live
Registered
76th of 85
by date

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 32nd largest by planned enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 49 with no phase, reaches primary completion later than 18 of the 33 other live ones, and was the 76th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to improve quality of life in Parkinson's Disease (PD) patients by increasing their empathy and their (self-)compassion. The main question it aims to answer is:

Does the level of quality of life in PD patients and caregivers improve after empathy/(self-)compassion training?

Participants will be delivered a 6-week empathy and compassion training (mindfulness, writing and poetry exercises addressing the cognitive, emotional, motivational and behavioural components of (self-)compassion) and will also be asked to answer questionnaires before and after the training

03

Conditions studied

  • Parkinson Disease(PD)

Browse trials for

Keywords

  • Empathy
  • (self-)compassion
  • Parkinson disease (PD)
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of PD
  • Hoehn and Yahr scale, stage ≤ 3
  • with a score ≥ 26
  • Able to give as documented by signature
  • At least, secondary school education
  • To have a regular caregiver at home

Exclusion Criteria:

  • Any medical condition that is not PD, such as drug induced parkinsonism
  • Major depression, dysthymia, or according to
  • Other neurological or psychiatric diseases
  • Neuropsychological scores compatible with the diagnosis of early dementia
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc

For CAREGIVERS:

Inclusion criteria

  • Taking care of the patient on a regular basis, i.e., at least 3 days per week
  • Being caregiver of the patients for at least 3 months
  • At least, secondary school education
  • Written informed consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Empathy and (self-)compassion training

    A 6-week empathy and compassion training will be designed and delivered involving PD patients and caregivers. During the compassion training participants will do mindfulness, writing and poetry exercises addressing the cognitive, emotional, motivational and behavioural components of (self-)compassion. The training will be designed in order to address both self-compassion and compassion. We expect to conduct 1 session at the beginning and 1 session at the end of the program with exercises to do at home for 6 weeks, assigned as tasks based on the needs of patients and their caregivers

    Behavioral: empathy and compassion training

Interventions

  • Behavioralempathy and compassion training

    A 6-week empathy and compassion training will be designed and delivered involving PD patients and caregivers. During the compassion training participants will do mindfulness, writing and poetry exercises

06

What researchers measure

Primary outcomes

  1. PD patients quality of life improvement

    the change (no min / max values foreseen) in the level of quality of life in PD patients as measured by the Parkinson's Disease Questionnaire (PDQ-8), which assesses 8 domains of quality of life: mobility, activities of daily of living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort; higher scores indicate a worse quality of life

    Time frame: from baseline to the end of intervention (6weeks)

Secondary outcomes

  1. change in the level of empathy in PD patients and caregivers

    change in the level of empathy in PD patients and caregivers as measured by Interpersonal Reactivity Index (IRI): this questionnaire captures both the cognitive and emotional facets of empathy. It includes four seven-item subscales: 1) Fantasy (F) and 2) Perspective Taking (PT) for the cognitive dimension and 3) Empathic Concern (EC) and 4) Personal Distress (PersDis) for an emotional one. The F scale assesses the tendency to identify oneself imaginatively in characters and situations (for example, movie characters and novels); the PT scale contains elements that map to the ability to apply the perspectives of other people from their point of view; the EC scale evaluates feelings of compassion and concern regarding other people; the PersDis measures the personal feelings of anxiety and discomfort that are experienced by observing the negative emotion

    Time frame: from baseline to the end of intervention (6weeks)

  2. self-compassion level change in PD patients and caregivers

    change in the level of self-compassion in PD patients and caregivers as measured by Self-Compassion Scale (SCS): this is a 26-item validated questionnaire which measures self-compassion with six subscales: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Past studies used this test with people with Parkinson's . The total self-compassion score is the mean of the six subscale means and ranges from 1 to 5, with a higher score indicating greater self-compassion

    Time frame: from baseline to the end of intervention (6weeks)

  3. compassion level change in PD patients and caregivers

    change in the level of compassion in PD patients and caregivers as a derived measure of the SCS: a 26-item validated questionnaire, measures self-compassion with six subscales: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Past studies used this test with people with Parkinson's. The total self-compassion score is the mean of the six subscale means and ranges from 1 to 5, with a higher score indicating greater self-compassion

    Time frame: from baseline to the end of intervention (6weeks)

  4. quality of life level change in caregivers

    change in the level of quality of life in caregivers as measured by the Family Caregiver Quality of Life Scale (FAMQOL): it evaluates caregivers' quality of life across multiple dimensions (physical, psychological, and social well-being). The FAMQOL consists of 16 self-reported questions with 5-option Likert responses, ranging from "Strongly Disagree" to "Strongly Agree"

    Time frame: from baseline to the end of intervention (6weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 20 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 31, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07097298
Lead sponsor
Alain Kaelin
Collaborators
CTU-EOC Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Alain Kaelin (Prof. MD PhD, Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
Jul 31, 2025
Start date
Nov 6, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Dec 1, 2025

Study contacts

Alain Kaelin, Prof. MD PhD
Contact
alain.kaelin@eoc.ch
+41918117342

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion